Bibliography
- KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
- CARTER PJ: Potent antibody therapeutics by design. Nat. Rev. Immunol. (2006) 6:343-357.
- VOSE JM, LINK BK, GROSSBARD ML et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. (2001) 19:389-397.
- SACCHI S, FEDERICO M, VITOLO U et al.: Clinical activity and safety of combination immunotherapy with IFN-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica. (2001) 86:951-958.
- McLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 mAb therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programme. J. Clin. Oncol. (1998) 16:2825-2833.
- GOVINDAN R: Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. (2004) 10:4241s-4244s.
- FRIEDBERG JW, NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with rituximab and IL-2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. (2002) 117:828-834.
- BURSTEIN HJ, KUTER I, CAMPOS SM et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2001) 19:2722-2730.
- HAINSWORTH JD: Prolonging remission with rituximab maintenance therapy. Semin. Oncol. (2004) 31:17-21.
- SHIELDS RL, NAMENUK AK, HONG K et al.: High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. (2001) 276:6591-6604.
- LI H, SETHURAMAN N, TADHEIM TA et al.: Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. (2006) 24:210-215.
- IDUSOGIE EE, PRESTA LG, GAZZANO-SANTORO H et al.: Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. (2000) 164:4178-4184.
- CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 mAb and polymorphism in IgG Fc receptor FcγRIIIα gene. Blood (2002) 99:754-758.
- JAZIREHI AR, BONAVIDA B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene (2005) 24:2121-2143.
- KABBAT EA, WU TT, PERRYHM, GOTTESMAN KS, FOELLER C: Sequences of proteins of immunological interest, US department of Health and Human Services, Public Health Services, National Institute of Health (1991).
Website
- www.fda.gov The US Food & Drug Administration website.